NASDAQ:PLUR Pluri (PLUR) Stock Price, News & Analysis $3.92 +0.31 (+8.43%) Closing price 04/17/2025 03:51 PM EasternExtended Trading$4.23 +0.30 (+7.67%) As of 04/17/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Pluri Stock (NASDAQ:PLUR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pluri alerts:Sign Up Key Stats Today's Range$3.36▼$4.0450-Day Range$3.58▼$4.7252-Week Range$3.33▼$6.60Volume32,129 shsAverage Volume13,622 shsMarket Capitalization$27.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.Read More… Pluri Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScorePLUR MarketRank™: Pluri scored higher than 18% of companies evaluated by MarketBeat, and ranked 837th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Pluri. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Pluri is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pluri is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Pluri's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.21% of the float of Pluri has been sold short.Short Interest Ratio / Days to CoverPluri has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pluri has recently decreased by 58.56%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPluri does not currently pay a dividend.Dividend GrowthPluri does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.21% of the float of Pluri has been sold short.Short Interest Ratio / Days to CoverPluri has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pluri has recently decreased by 58.56%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.59 News SentimentPluri has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Pluri this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Pluri to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pluri insiders have not sold or bought any company stock.Percentage Held by Insiders10.20% of the stock of Pluri is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.59% of the stock of Pluri is held by institutions.Read more about Pluri's insider trading history. Receive PLUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pluri and its competitors with MarketBeat's FREE daily newsletter. Email Address PLUR Stock News HeadlinesIn case of a nuclear event, Ukraine to use Israeli placenta-based emergency treatmentApril 20 at 10:30 AM | msn.comFinancial Comparison: Prime Medicine (NYSE:PRME) vs. Pluri (NASDAQ:PLUR)April 17 at 3:19 AM | americanbankingnews.comTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you ready for it?April 20, 2025 | Porter & Company (Ad)Pluri announces USPTO issued patent covering its immune cell expansion techApril 12, 2025 | markets.businessinsider.comPluri’s immune cell expansion technologies gain patentsApril 11, 2025 | finance.yahoo.comPluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and IsraelApril 10, 2025 | finance.yahoo.comUsing cell science to fight nuclear weapons: How is Pluri revolutionizing health and food tech?March 14, 2025 | msn.comPluri announces exclusive collaboration agreement with HemafundMarch 5, 2025 | markets.businessinsider.comSee More Headlines PLUR Stock Analysis - Frequently Asked Questions How have PLUR shares performed this year? Pluri's stock was trading at $4.28 on January 1st, 2025. Since then, PLUR stock has decreased by 8.3% and is now trading at $3.9250. View the best growth stocks for 2025 here. How were Pluri's earnings last quarter? Pluri Inc. (NASDAQ:PLUR) announced its quarterly earnings data on Tuesday, February, 11th. The company reported ($0.53) earnings per share (EPS) for the quarter. Pluri had a negative trailing twelve-month return on equity of 2,778.13% and a negative net margin of 3,551.49%. When did Pluri's stock split? Pluri shares reverse split on the morning of Monday, April 1st 2024. The 1-8 reverse split was announced on Monday, April 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. How do I buy shares of Pluri? Shares of PLUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pluri own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pluri investors own include Digital Turbine (APPS), Lightning eMotors (ZEV), Archer Aviation (ACHR), ChargePoint (CHPT) and Canoo (GOEV). Company Calendar Last Earnings2/11/2025Today4/20/2025Next Earnings (Estimated)5/08/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PLUR CIK1158780 Webpluri-biotech.com Phone972747108600Fax972-74-710-8787Employees150Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,890,000.00 Net Margins-3,551.49% Pretax Margin-2,437.04% Return on Equity-2,778.13% Return on Assets-83.61% Debt Debt-to-Equity Ratio4.44 Current Ratio5.04 Quick Ratio5.04 Sales & Book Value Annual Sales$678,000.00 Price / Sales40.51 Cash FlowN/A Price / Cash FlowN/A Book Value($0.42) per share Price / Book-9.35Miscellaneous Outstanding Shares6,997,000Free Float6,283,000Market Cap$27.46 million OptionableOptionable Beta1.95 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:PLUR) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.